| Description |
Cisapride : It is capable of correcting
abnormal motility through out the GI Tract. Cisapride
appears to be devoid of dopaminergic blocking activity
& it does not influence the concentration of prolactin
in plasma or cause extrapyramidal symptoms.
Simethicone :
|
| Composition |
Each Uncoated chewable tablet contains:Cisapride
B.P.Equivalent to Cisapride Anhydrous 10mgSimethicone
I.P. 125mg (Methyl Polysiloxane)Excipients q.s. Peppermint
FlavouredColour : Ponceau 4R
|
| Indications |
Cisapride: Non-ulcer dyspepsia
: Treatment of symptoms such as epigastric pain, early
satiety, bloating, where organic disease has been
excluded. Gasto-oesophageal reflux disease: Treatment
of symptoms such as heartburn, regurgitation &
for healing of mucosal lesions. Impaired gastric emptying
: Relief of symptoms such as epigastric pain, early
satiety, anorexia, bloating & nausea associated
with delayed gastric emptying secondary to systemic
sclerosis & autonomic neuropathy of diabetes-origin.
Chronic constipation.
Simethicone :
|
| Dosage |
|
| Pack |
10 Blisters of 10 Tablets each
|
